The following new members were elected to the Rein in Sarcoma Board of Directors at the January 25 2021 Annual Meeting:
Dr. John Charlson
Dr. Charlson is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in sarcoma. He graduated from the University of Iowa, College of Medicine in 1999, and then completed an internal medicine residency at the Medical College of Wisconsin Affiliated hospitals, serving as chief resident. He completed his fellowship in oncology in 2007, and is board certified in medical oncology. Dr. Charlson is the Medical College of Wisconsin’s Principal Investigator for several sarcoma clinical trials.
Aaron Halbe
Aaron Halbe is a Director of Finance at UnitedHealthcare. After graduating college, he worked as an organic chemist, manufacturing active pharmaceutical ingredients in exploratory chemotherapy treatments. He went on to earn a Master’s degree in business, joined UnitedHealth Group and for the last 12 years has worked in the Corporate Development, Medicaid and Medicare businesses helping the company drive innovation in healthcare. Aaron’s family has a strong connection to healthcare, with multiple family members working in the industry, including his wife, who is a nurse of 15 years, who has worked in hematology/oncology, the ICU, and current works in cardiology.
Dr. Stephanie Terezakis
Dr. Terezakis is the Chair of Radiation Oncology at the University of Minnesota, and focuses her clinical practice on pediatric cancers, hematologic malignancies including lymphoma, as well as musculoskeletal tumors. Her clinical and translational research incorporates advanced diagnostic radiology techniques into the radiation treatment planning of cancers to minimize long-term side effects and improve efficacy of treatment. She is also an active investigator of stereotactic body radiation therapy techniques in pediatric and adult tumors. Dr. Terezakis is a leader within the Children’s Oncology Group that develops and runs national clinical trials for children with cancer as well as multiple national committees that establish the standard of care for cancer treatment.
